World’s first mRNA lung cancer vaccine trials begin in Europe | Current Affairs | Vision IAS
News Today Logo

World’s first mRNA lung cancer vaccine trials begin in Europe

Posted 24 Aug 2024

2 min read

Vaccine BNT116 is designed to treat non-small cell lung cancer, the most common type of lung cancer

  • Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8million deaths every year.

Vaccine is based on mRNA (messenger Ribonucleic Acid) technology.

  • This technology is seen as the next big phase of cancer treatment.

About mRNA Vaccine Technology

  • Working Mechanism:
    • It works by introducing a piece of mRNA that corresponds to a viral protein, usually a small piece of a protein found on the virus’s outer membrane. 
      • mRNA is a genetic molecule that contains instructions or recipe that directs cells to make a protein using its natural machinery.
    • This mRNA prompts cells to create viral proteins, triggering the immune system to produce antibodies and boost the immune system.
      • E.g., the mRNA vaccine for COVID-19 directed cells to produce copies of a protein on the outside of the coronavirus known as the spike protein.
  • Benefits:  
    • Safer as it do not contain any live or weakened viruses.
    • Also, can be developed quickly, unlike other traditional vaccines, which can take months to produce by growing weakened forms of the virus. 
  • Tags :
  • mRNA Vaccine
  • Immune System
  • Non-Small Cell Lung Cancer
Watch News Today